Indaptus Therapeutics Reports Third Quarter 2026 Financial Results
Indaptus Therapeutics announced its financial results for the third quarter of 2026, highlighting a decrease in net loss and research and development expenses.
Stocks · News reference
Nir Sassi, the former Chief Financial Officer of Indaptus Therapeutics, has been appointed as the new CFO of Nasus Pharma, effective November 11, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Indaptus Therapeutics announced its financial results for the third quarter of 2026, highlighting a decrease in net loss and research and development expenses.
Filed: 2026-11-13 AccNo: 0001493152-26-051749 Size: 365 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
U.S. futures mixed; Netflix fell 6% after mixed Q3 results and weaker guidance. Alpha Teknova, Intuitive Surgical and others also declined premarket.
U.S. stocks mixed; Dow up ~200 points. Penske Automotive surged on a $16.3B go-private deal, while OPKO, Ericsson and others rallied.
U.S. stocks fell, but Radiant Logistics surged 17.8% after beating Q4 estimates. Waystar, Telix and Forgent also posted strong gains.
U.S. stocks rose Friday, led by Nasdaq +0.97%; Kroger beat estimates. Oil fell 2.7%, consumer sentiment weakened, and Asian markets declined.